Madsen Kenneth L, Beuming Thijs, Niv Masha Y, Chang Chiun-Wen, Dev Kumlesh K, Weinstein Harel, Gether Ulrik
Molecular Neuropharmacology Group, Department of Pharmacology, The Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark.
J Biol Chem. 2005 May 27;280(21):20539-48. doi: 10.1074/jbc.M500577200. Epub 2005 Mar 17.
PICK1 (protein interacting with C kinase 1) contains a single PDZ domain known to mediate interaction with the C termini of several receptors, transporters, ion channels, and kinases. In contrast to most PDZ domains, the PICK1 PDZ domain interacts with binding sequences classifiable as type I (terminating in (S/T)XPhi; X, any residue) as well as type II (PhiXPhi; Phi, any hydrophobic residue). To enable direct assessment of the affinity of the PICK1 PDZ domain for its binding partners we developed a purification scheme for PICK1 and a novel quantitative binding assay based on fluorescence polarization. Our results showed that the PICK1 PDZ domain binds the type II sequence presented by the human dopamine transporter (-WLKV) with an almost 15-fold and >100-fold higher affinity than the type I sequences presented by protein kinase Calpha (-QSAV) and the beta(2)-adrenergic receptor (-DSLL), respectively. Mutational analysis of Lys(83) in the alphaB1 position of the PDZ domain suggested that this residue mimics the function of hydrophobic residues present in this position in regular type II PDZ domains. The PICK1 PDZ domain was moreover found to prefer small hydrophobic residues in the C-terminal P(0) position of the ligand. Molecular modeling predicted a rank order of (Val > Ile > Leu) that was verified experimentally with up to a approximately 16-fold difference in binding affinity between a valine and a leucine in P(0). The results define the structural basis for the unusual binding pattern of the PICK1 PDZ domain by substantiating the critical role of the alphaB1 position (Lys(83)) and of discrete side chain differences in position P(0) of the ligands.
PICK1(与C激酶1相互作用的蛋白质)含有一个单一的PDZ结构域,已知该结构域可介导与多种受体、转运蛋白、离子通道和激酶的C末端相互作用。与大多数PDZ结构域不同,PICK1 PDZ结构域与可分类为I型(以(S/T)XPhi结尾;X为任意残基)以及II型(PhiXPhi;Phi为任意疏水残基)的结合序列相互作用。为了能够直接评估PICK1 PDZ结构域与其结合伙伴的亲和力,我们开发了一种PICK1的纯化方案以及一种基于荧光偏振的新型定量结合测定法。我们的结果表明,PICK1 PDZ结构域与人多巴胺转运体呈现的II型序列(-WLKV)结合的亲和力分别比蛋白激酶Cα呈现的I型序列(-QSAV)和β2-肾上腺素能受体呈现的I型序列(-DSLL)高近15倍和>100倍。对PDZ结构域αB1位置的赖氨酸(Lys83)进行突变分析表明,该残基模拟了常规II型PDZ结构域中该位置存在的疏水残基的功能。此外,发现PICK1 PDZ结构域在配体的C末端P0位置更喜欢小的疏水残基。分子建模预测的顺序为(缬氨酸>异亮氨酸>亮氨酸),这通过实验得到了验证,缬氨酸和亮氨酸在P0位置的结合亲和力差异高达约16倍。这些结果通过证实αB1位置(Lys83)和配体P0位置离散的侧链差异的关键作用,确定了PICK1 PDZ结构域异常结合模式的结构基础。